🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

LEXX LEXX

Company Profile ↓
$5.67
+548.00% 1Y
P/E-8.59
52W High$22.95
52W Low$0.88
EPS (TTM)$-0.66

Company Overview

LEXX (LEXX) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.

Why Investors Should Care

Steady Revenue Expansion

Revenue has grown at a 12.9% CAGR over the past five years.

Recent Developments

  • Aug 2025 Revenue of $705.92K (+52.0% YoY); net profit $-11.90M.
  • Trailing 12 Months Year-on-year growth — revenue +52.0%.
  • 5-Year Trend Long-term compounding — revenue CAGR 12.9%.

Growth & Price Performance

Compounded Sales Growth

5 Years:12.92%
1 Year:52.05%

Stock Price Performance

1 Year:+548.00%
6 Months:-50.65%
3 Months:-45.45%
1 Month:-28.68%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 22% of range
$0.88 $22.95
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)34.23 · Neutral
Price Performance
1M-28.68%
3M-45.45%
6M-50.65%
1Y+548.00%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 12.9% over 5 years.

CONS

  • Trading 75.3% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-8.59
Industry PE
-
Forward P/E
-
PEG Ratio
-
Book Value
$-
Price to Book
-
P/S
-
EV/EBITDA
-
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
12.92%
Profit 5Y
-
Revenue (YoY)
52.05%
Earnings (YoY)
-

Profitability & Returns

ROCE
-
ROE
-
ROA
-
Profit Margin
-
Op Margin
-
Gross Margin
99.61%
EPS (Latest Qtr)
$-0.08
EPS (TTM)
$-0.66

Balance Sheet & Liquidity

Debt/Equity
-
Quick Ratio
-
Current Ratio
-
Debt
-
Total Assets
$4.78M
Current Assets
-
Working Capital
-

Ownership

Promoter Holding
-
Chg in Prom Hold
-
FII / Inst Holding
-
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
-
Total Revenue (TTM)
$705.92K
EBITDA
-
Free Cash Flow
$-10.48M
Operating Cash Flow
$-10.45M
Shares Outstanding
-
Gross Margin
99.61%
Payout Ratio
-
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Apr 2014May 2014Jul 2014Nov 2014Feb 2015May 2015Nov 2015Feb 2016May 2016Nov 2016Feb 2017May 2017Nov 2017Feb 2018May 2018Nov 2018Feb 2019May 2019Nov 2019Feb 2020May 2020Nov 2020Feb 2021May 2021Aug 2021Nov 2021Feb 2022May 2022Nov 2022Feb 2023May 2023Nov 2023Feb 2024May 2024Nov 2024Feb 2025May 2025Nov 2025Feb 2026May 2026
Revenue ------------24.64K171.96K140.34K22.21K15.35K59.93K10.33K37.55K36.42K295.66K192.01K204.06K-13.88K--97.73K--151.28K--183.92K-----
Gross Profit 57.54K053.76K0831-2.50K-3.60K-4.08K-3.09K8.34K-2.27K20.07K18.54K158.25K137.91K20.05K12.66K56.84K2.48K-20.56K16.10K231.18K161.44K144.07K-8.31K24.26K81.08K81.94K17.07K64.96K146.46K145.00K84.00K181.20K174.00K174.00K020.00K0
Operating Income ---567.95K-398.07K-458.61K-511.01K-411.74K-274.56K-264.20K-400.55K---578.71K-----------2.57M----2.42M-1.70M-1.32M-2.40M-1.14M-668.00K-1.74M-2.69M-2.75M-3.75M-1.57M-1.45M-1.99M
Net Income ----398.07K---411.74K------578.71K---701.39K---924.76K-997.49K-1.39M-710.12K393.19K-2.57M-1.18M-1.99M-1.43M-2.38M-1.76M-1.30M-2.37M-1.18M-649.54K-1.78M-2.70M-2.71M-3.79M-1.60M-1.45M-1.99M
Diluted EPS --------------------------------0.13-0.06-0.13-0.16-0.15-0.21-0.07-0.06-0.08
R&D Expense -0-48.04K2401071.98K6.85K1587.26K7.78K8.24K110.39K75.76K93.07K96.97K66.08K231.03K107.46K186.56K24.56K192.26K176.40K454.44K-458.71K275.69K752.10K829.49K696.18K1.64M574.49K245.78K573.09K1.95M1.69M2.72M671.34K475.39K970.83K

Profit & Loss (Annual)

Figures in USD.

Metric Oct 2010Oct 2011Oct 2012Oct 2013Aug 2014Aug 2015Aug 2016Aug 2017Aug 2018Aug 2019Aug 2020Aug 2021Aug 2022Aug 2023Aug 2024Aug 2025
Revenue ----014.70K40.72K63.64K433.29K222.61K384.54K722.74K255.40K226.21K464.28K705.92K
Gross Profit 88.86K465.91K574.49K302.25K0-15.18K-4.90K33.89K408.10K199.72K215.41K547.39K183.56K194.71K459.46K703.20K
Operating Income -----1.56M-1.98M-1.28M-----5.69M-6.62M-6.53M-5.75M-11.88M
Net Income -552.46K-538.23K---1.56M-1.98M-1.28M-1.93M-6.61M-4.16M-4.08M-4.03M-7.27M-6.66M-5.80M-11.90M
Diluted EPS -0.04-0.04------------1.01-0.47-0.66
R&D Expense ----0146.47K9.02K54.19K492.86K555.73K387.07K1.26M1.84M3.67M2.36M8.24M

Balance Sheet (Annual)

Figures in USD.

Metric Oct 2009Oct 2010Oct 2011Oct 2012Aug 2013Oct 2013Aug 2014Aug 2015Aug 2016Aug 2017Aug 2018Aug 2019Aug 2020Aug 2021Aug 2022Aug 2023Aug 2024Aug 2025
Total Assets -3.28M4.34M4.19M-3.57M2.64M711.72K566.64K2.86M2.43M2.68M2.83M13.27M7.83M3.08M8.87M4.18M
Total Equity 2.30M2.15M2.66M2.42M-2.10M1.72M772.41K266.05K2.77M2.39M2.49M2.48M13.27M7.95M3.04M8.04M2.99M
Cash & Equivalents 330.17K62.99K31.20K180.51K65.54K65.54K703.03K260.07K93.41K2.53M1.73M1.29M1.29M10.92M5.81M---
Total Liabilities -1.12M1.68M1.77M-1.47M918.04K55.12K478.88K92.35K43.64K184.51K345.98K203.26K201.44K403.91K1.21M1.57M
Current Liabilities -1.05M1.08M1.71M-1.42M918.04K55.12K433.88K92.35K43.64K184.51K225.92K153.28K194.04K267.74K1.10M1.49M

Cash Flows (Annual)

Figures in USD.

Metric Oct 2010Oct 2011Oct 2012Oct 2013Aug 2014Aug 2015Aug 2016Aug 2017Aug 2018Aug 2019Aug 2020Aug 2021Aug 2022Aug 2023Aug 2024Aug 2025
Operating Cash Flow -330.34K109.84K135.94K321.00K-515.82K-1.50M-660.86K-1.55M-2.52M-3.01M-2.62M-3.99M-4.88M-5.88M-4.96M-10.45M
Investing Cash Flow -285.24K-1.00M-274.13K-70.61K-76.29K684.82K-20.10K-9.70K-155.40K-769.16K-26.84K193.88K-180.64K-169.61K-188.60K-243.02K
Financing Cash Flow 348.40K861.00K287.50K-365.36K1.23M373.25K514.29K4.00M1.87M3.33M2.65M13.42M-44.60K1.59M10.32M6.05M
Capital Expenditure ------0-3.09K-0--646.18K-0--49.19K-33.75K-43.01K-24.65K
Free Cash Flow ------1.50M-663.95K-1.55M--3.65M-2.62M--4.93M-5.91M-5.00M-10.48M

Ratios (Annual)

Figures in %.

Metric Oct 2010Oct 2011Oct 2012Oct 2013Aug 2014Aug 2015Aug 2016Aug 2017Aug 2018Aug 2019Aug 2020Aug 2021Aug 2022Aug 2023Aug 2024Aug 2025
Gross Margin % ------103.3%-12.0%53.3%94.2%89.7%56.0%75.7%71.9%86.1%99.0%99.6%
Operating Margin % ------13,489.8%-3,136.8%-----786.8%-2,591.7%-2,888.5%-1,239.2%-1,683.0%
Net Margin % ------13,489.8%-3,136.8%-3,031.9%-1,525.4%-1,868.0%-1,062.2%-557.2%-2,846.3%-2,946.4%-1,248.2%-1,686.0%
ROE % -25.7%-20.2%---90.8%-256.8%-480.1%-69.7%-276.7%-167.0%-164.6%-30.4%-91.5%-218.9%-72.1%-398.1%
ROCE % -----90.8%-302.1%-962.1%-----43.4%-86.6%-232.0%-74.1%-443.0%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for LEXX

Yahoo Finance hu, 30 Jul 2026

Lexaria Announces Effective Date for Reverse Stock Split

KELOWNA, BC / ACCESS Newswire / July 30, 2026 / Lexaria Bioscience Corp. (Nasdaq:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it intends to effect a reverse stock split of its common stoc…

Yahoo Finance Fri, 17 Jul 2026

LEXX: Dosing Started for Animal & Human GLP-1 Studies

By John Vandermosten, CFA NASDAQ: LEXX READ THE FULL LEXX RESEARCH REPORT We update our report on Lexaria Bioscience Corporation (NASDAQ: LEXX) on the occasion of its third quarter fiscal 2026 Form 10-Q filing. Beyond the financial update, …

Yahoo Finance Mon, 06 Jul 2026

Lexaria Updates Business Development

KELOWNA, BC / ACCESS Newswire / July 6, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to have experienced many positive meetings with potential pharmace…

Yahoo Finance hu, 25 Jun 2026

Lexaria's Human Study GLP-1-H26-7 Has Begun Dosing on Schedule

KELOWNA, BC / ACCESS Newswire / June 25, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that dosing began on schedule on June 14th with Human Pilot Study …

Yahoo Finance ue, 23 Jun 2026

Lexaria's Animal Study GLP-1-A26-1 Has Begun Dosing on Schedule

Potentially Valuable Novel Compositions Being Investigated Lexaria Also Receives Additional New Granted Patent KELOWNA, BC / ACCESS Newswire / June 23, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global inn…

Yahoo Finance Wed, 17 Jun 2026

GLP-1 'Arms Race' Intensifies as the Addressable Markets Continue to Expand

More People Than Ever Taking GLP-1 Drugs for Weight Loss Growing List of Diseases Now Indicated as Treatable With GLP-1 Drugs KELOWNA, BC / ACCESS Newswire / June 17, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"…

LEXX — Frequently Asked Questions

What is the current share price of LEXX?

As of 2026-08-05 17:25 PDT, LEXX trades at $5.67 on NASDAQ/NYSE. Its 52-week range is $0.88 to $22.95.

What is the P/E ratio of LEXX?

LEXX trades at a trailing price-to-earnings (P/E) ratio of -8.59.

Is LEXX a good stock to buy?

This page provides a data-driven analysis of LEXX, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space